AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01826851 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exparel
Description: Patients in this group will receive 266 mg Exparel diluted with 0.9% normal saline to a total volume of 50 mL and administered via parasternal intercostal nerve block prior to sternal closure.~Post-operatively, patients will receive IV fentanyl as needed in the ICU while still intubated. A fentanyl PCA pump will be set up post-extubation as soon as possible and prior to the patient leaving the ICU.
Study NCT01826851 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients in this group will receive 50 mL of 0.9% normal saline as a parasternal intercostal nerve block prior to sternal closure.~Post-surgical pain management will be the same as for the Exparel group.
Study NCT03482687 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Me & You: Building Healthy Relationships
Description: Me \& You: Building Healthy Relationships is a classroom- and computer-based healthy relationships curriculum for middle school students. It consists of thirteen 25-minute lessons: 5 classroom, 5 computer-only, and 3 classroom-computer hybrid. The curriculum integrates group-based classroom activities (e.g., role-plays, group discussion, and other skill-building activities) and computer-based activities, some of which are individually tailored. The curriculum was adapted from an existing effective sex education and relationship curriculum, It's Your Game...Keep it Real (IYG), which was enhanced to more explicitly address teen dating violence (TDV).
Study NCT03300167 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Liquid Biopsy System
Description: The Liquid Biopsy System is a single use percutaneously-delivered coronary blood sampling device designed to collect blood samples from within a target coronary artery so that the blood can be analysed.
Study NCT02379767 — intervention group
Intervention type: DEVICE
Intervention: Electroconvulsive therapy
Study NCT02379767 — intervention group
Intervention type: OTHER
Intervention: Positron emission tomography of the brain using [11C]harmine
Study NCT02379767 — intervention group
Intervention type: OTHER
Intervention: Structural magnetic resonance imaging
Study NCT05132270 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydroxyurea and thalidomide
Description: Evaluation of hydroxyurea and thalidomide combination use in beta-thalassemia patients
Study NCT04475900 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Corneal biomechanics (Corvis ST, Oculus, Wetzlar, Germany)
Description: To measure corneal biomechanics with Scheimpflug based tonometry
Study NCT04475900 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Corneal topography and tomography (Pentacam, Oculus, Wetzlar, Germany)
Description: To measure corneal topography and tomography with Scheimpflug tomograph
Study NCT04475900 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Optic nerve head measurement
Description: To measure optic nerve excavation
Study NCT03960073 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: MitoQ
Description: 4 week 20mg oral daily dose of Mito Q
Study NCT03960073 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 4 week oral daily dose of TTP placebo
Study NCT01701999 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rBV A/B
Description: rBV A/B injections will consist of a single 40 µg injection of total antigen (20 µg of Antigen A and 20 µg of Antigen B) adsorbed to 0.2% (wt/vol) Alhydrogel™, in a total dose volume of 0.5 mL. The vaccine will be administered by intramuscular injection in the deltoid muscle, preferably in the nondominant arm.
Study NCT00058474 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: 825 mg/m2 oral daily 5 days a week on days of planned RT
Study NCT00058474 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluorouracil
Description: 225 mg/m2 IV daily continuous infusion
Study NCT00058474 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: 225 mg/m2 IV daily continuous infusion
Study NCT00058474 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: 50 mg/m2 IV 5 days a week on days of planned RT
Study NCT00058474 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiation therapy
Description: Given 5 days a week for 5-6 weeks
Study NCT00058474 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Given 5 days a week for 5-6 weeks
Study NCT02729740 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Penumbra Smart Coil
Study NCT02729740 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Penumbra Coil 400TM (PC400), Penumbra Occlusion DeviceTM(POD)
Description: Other Penumbra Coils available as standard of care
Study NCT00298025 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetrotide®
Description: Cetrotide® will be administered subcutaneously as 3 mg injection when the lead follicle is >=14 mm till r-hCG day. If the subject did not achieve follicular maturation and did not receive r-hCG within 4 days, then the Cetrotide® will be administered at dose of 0.25 mg subcutaneously on successive days until r-hCG day.
Study NCT00298025 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antagon ™
Description: Antagon™ will be administered subcutaneously at a dose of 0.25 mg once daily when the lead follicle is >=14 mm until r-hCG day.
Study NCT00298025 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant human follicle stimulating hormone (r-hFSH)
Description: Recombinant human follicle stimulating hormone (r-hFSH) will be administered at a starting dose of 225 international unit (IU) subcutaneously once daily from S1 up to Stimulation Day 5 (S5). Beginning on Stimulation Day 6 (S6), the r-hFSH dose will be individualized to the subject. The minimum and maximum daily doses are 75 IU and 450 IU, respectively until r-hCG day.
Study NCT00298025 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant human follicle stimulating hormone (r-hFSH)
Description: Recombinant human follicle stimulating hormone (r-hFSH) will be administered at a starting dose of 225 international unit (IU) subcutaneously once daily from S1 up to Stimulation Day 5 (S5). Beginning on Stimulation Day 6 (S6), the r-hFSH dose will be individualized to the subject. The minimum and maximum daily doses are 75 IU and 450 IU, respectively until r-hCG day.
Study NCT00298025 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Human Menopausal Gonadotropin (hMG)
Description: Human menopausal gonadotropin (hMG) will be administered subcutaneously daily at a dose of 75 IU till r-hCG day. The total daily dose of r-hFSH and hMG combined is not to exceed 450 IU (375 IU r-hFSH and 75 IU hMG).
Study NCT00298025 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human Menopausal Gonadotropin (hMG)
Description: Human menopausal gonadotropin (hMG) will be administered subcutaneously daily at a dose of 75 IU till r-hCG day. The total daily dose of r-hFSH and hMG combined is not to exceed 450 IU (375 IU r-hFSH and 75 IU hMG).
Study NCT00298025 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant Human Choriogonadotropin (r-hCG)
Description: The r-hCG will be administered as a single dose of 250 microgram (mcg) subcutaneously when there is at least one follicle of >=18 mm and two additional follicles of >=16 mm with an appropriate plasma estradiol levels for the number and size of the existing follicles. The r-hCG will be administered within 36 hours after the last dose of the r-hFSH/hMG.
Study NCT00298025 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Human Choriogonadotropin (r-hCG)
Description: The r-hCG will be administered as a single dose of 250 microgram (mcg) subcutaneously when there is at least one follicle of >=18 mm and two additional follicles of >=16 mm with an appropriate plasma estradiol levels for the number and size of the existing follicles. The r-hCG will be administered within 36 hours after the last dose of the r-hFSH/hMG.
Study NCT06424951 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LKCM(Loving-kindness and Compassion Meditations)
Description: Loving-kindness and Compassion Meditations
Study NCT01961401 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise
Study NCT00882310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Days 4 and 11: gemcitabine 600 mg/m2 over 60 mins intravenous (IV) followed by docetaxel 30 mg/m2 over 60 mins IV
Study NCT00882310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Days 4 and 11: gemcitabine 600 mg/m2 over 60 mins intravenous (IV) followed by docetaxel 30 mg/m2 over 60 mins IV
Study NCT00882310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Day 1-14: capecitabine at 1000 mg/m2/day divided into 2 doses given two times a day (BID) by mouth (PO) Maximum dose 2000mg/day divided into BID dosing
Study NCT04077541 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: internet platform
Description: The trauma care bundles combined with the internet platform.
Study NCT00537498 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Urokinase
Description: Daily intravenous application of urokinase over 30 minutes~Dosage:~If plasma fibrinogen is > 2,5g/l application of 1 000 000 IU Urokinase If plasma fibrinogen is \< 2,5g/l application of 500 000 IU Urokinase If plasma fibrinogen is \< 1,6g/l treatment must be stopped and continued after rising up to >2g/l
Study NCT02654366 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Risk Reduction Group
Description: The Risk Reduction and Treatment Readiness skills component includes six modules: 1) BNEP services and substance abuse treatment; 2) nature of chemical dependence (severity/chronicity and medical aspects); 3) infectious diseases (HIV and Hepatitis C virus (HCV) information); 4) injection drug use risk reduction (effective equipment cleaning and drug-splitting techniques); 5) sex risk reduction (reducing high-risk behaviors and effective condom use); and 6) overdose prevention.~The Community Outreach skills component is devoted to discussing the benefits of recovery-focused social support, and directing BNEP registrants and their CSPs to participate in activities together (as determined in the group session) at least 1 time per week to work toward expanding the scope of drug-free social support.
Study NCT03032406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Hydroxychloroquine
Study NCT03032406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Everolimus
Study NCT00698932 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin
Description: 5mg, oral tablet, once daily for 24 weeks
Study NCT00698932 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral tablet, once daily for 24 weeks
Study NCT02756351 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CytaCoat Nasal Prong
Study NCT02756351 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Inspiration Healthcare Inspire nCPAP Nasal Prong
Study NCT04263012 — intervention group
Intervention type: OTHER
Intervention: collection of patient data
Description: assess mortality rate, rehospitalization and survival rate of patients after receiving an artificial heart implant
Study NCT02773030 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-220
Description: Specified dose on specified days
Study NCT02773030 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Specified dose on specified days
Study NCT02773030 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Specified dose on specified days
Study NCT02773030 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Specified dose on specified days
Study NCT02773030 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Specified dose on specified days
Study NCT01653964 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Molecular breast imaging
Description: Molecular breast imaging performed with injection of Tc-99m sestamibi and a dedicated gamma camera (Luma Gem, Gamma Medica)
Study NCT02014740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide
Description: Liraglutide (Victoza) is an acylated analogue of glucagon-like peptide-1 (GLP-1) indicated for the treatment of type 2 diabetes mellitus• L-group will be started and dose-escalated to 1.8mg sc once daily according to below schedule: Liraglutide will be administered with a starting dose of 0.6 mg (after a least one week) and subsequent increments to 1.2 mg (after a least one week) and to 1.8 mg (after at least a week on 1.2 mg). L-group subjects will need to achieve the final dose of 1.8 mg by at least three weeks from the starting dose. Subjects who would not be able to achieve the dose of 1.8 mg (due to potential side effects) will be advised to lower the dose to 1.2 mg. Metformin regimen will be continued. .
Study NCT02014740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Study NCT02014740 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Study NCT03254654 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vinorelbine
Description: Experimental: 20 mg/m2, D6, D13, D20 Active Comparator: 25 mg/m2, D1, D8, D15
Study NCT03254654 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Description: Experimental: 20 mg/m2, D6, D13, D20 Active Comparator: 25 mg/m2, D1, D8, D15
Study NCT03254654 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: 250 mg/d, D1-5, D8-12, D15-19. The starting dose will be 250mg/d in the first cycle, if tolerable, 500 mg/d will be administered from the cycle 2.
Study NCT00005950 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nelarabine
Description: Given IV
Study NCT04246801 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clobetasol propionate
Description: Clobetasol propionate ophthalmic nanoemulsion 0.05%, is an oil-in-water (o/w), clear or slightly yellowish nanoemulsion containing the active ingredient clobetasol propionate at a concentration of 0.05% weight per weight (w/w)
Study NCT04246801 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Vehicle is identical in appearance and composition to clobetasol propionate ophthalmic nanoemulsion 0.05% but, without the active substance
Study NCT01083524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dichloroacetate Sodium
Description: 3 mg po bid for 28 weeks
Study NCT01083524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dichloroacetate Sodium
Description: 6.25 mg po bid
Study NCT01083524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dichloroacetate Sodium
Description: 12.5 mg po bid
Study NCT02201121 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Influences of phenylephrine, dopamine and ephedrine on stroke volume variation and pulse pressure variation
Description: This research mainly study the effect of clinical commonly used vasoconstrictor drugs on blood pressure of pressure
Study NCT03574857 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metolazone Oral Tablet
Description: Day 1: Metolazone 5 mg PO Day 2: Metolazone 5 mg PO
Study NCT03574857 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorothiazide Injection
Description: Day 1: Chlorothiazide 500 mg IV Day 2: Chlorothiazide 500 mg IV
Study NCT01882842 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endometrial biopsy
Description: Endometrial biopsy will be performed in the study group and timed according to a positive urinary LH (ovulation) kit at LH+7 to +9 days.
Study NCT01882842 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transvaginal ultrasound
Description: A detailed assessment of the endometrium will be performed including two- and three- dimensional ultrasound, as well as power Doppler acquisitions.
Study NCT00175877 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Certolizumab Pegol
Description: Strength and Form: Lyophilized product reconstituted to 1 ml containing 200 mg of Certolizumab Pegol (CZP) given as a subcutaneous injection.~Dosage and Frequency: 400 mg every two weeks for at least 6 months, then 200 mg every two weeks.~Duration: Until end of study.
Study NCT02748330 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: Ticagrelor
Study NCT02748330 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Clopidogrel
Study NCT03524508 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Onivyde
Description: The recommended dose and regimen of Onivyde is 70 mg/m2 intravenously over 90 minutes, followed by dl-LV 400mg/m2 or l-LV 200mg/m2 intravenously over 30 minutes, followed by 5-FU 2400 mg/m2 intravenously over 46 hours, administered every 2 weeks.
Study NCT03524508 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU/LV
Description: The recommended dose and regimen of dl-LV 400mg/m2 or l-LV 200mg/m2 intravenously over 30 minutes, followed by 5-FU 2400 mg/m2 intravenously over 46 hours, administered every 2 weeks
Study NCT03524508 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-FU/LV
Description: The recommended dose and regimen of dl-LV 400mg/m2 or l-LV 200mg/m2 intravenously over 30 minutes, followed by 5-FU 2400 mg/m2 intravenously over 46 hours, administered every 2 weeks
Study NCT00389259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: IV placebo q4h
Study NCT00389259 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IV placebo q4h
Study NCT01875094 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-Management / MTM using Health IT
Study NCT01455701 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Tocilizumab will be administered as indicated in the arm description.
Study NCT01093157 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adrenocorticotrophic hormone ACTH
Description: There will be two arms to the study: one arm receive 40 units and the second arm 80 units of the ACTH gel subcutaneously both given in a dose escalating frequency beginning at once every two weeks escalating to a maximum of twice per week over a total of three months exposed.An ammendment(approved by Health Canada and the UHN IRB allows an additional 1 month of the perscribed therapy of ACTH )if there is an improvement in proteinuria at the end of the 3 month exposure.
Study NCT02748330 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Acetylsalicylic acid
Study NCT02748330 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Acetylsalicylic acid
Study NCT00348920 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: High Spinal and General Anesthesia
Description: Spinal bupivacaine 0.75% in dextrose, 6 mls (45mg) and preservative free morphine 3 mcg/kg (to a maximum of 300 mcg).
Study NCT02867124 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: XR-NTX
Description: Vivitrol
Study NCT02867124 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XR-NTX
Description: Vivitrol
Study NCT02867124 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: place of residence
Description: One injection of XR-NTX in prison, followed by 6 monthly injections post-release at place of residence
Study NCT02867124 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: opioid treatment program
Description: One injection of XR-NTX in prison, followed by 6 monthly injections post-release at a community opioid treatment program
Study NCT03163784 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fecal Inoculum Capsule
Description: Sieved fecal matter prepared in glycerol/saline solution
Study NCT03163784 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for Fecal Inoculum Capsule)
Description: Placebo capsule manufactured to mimic Fecal Inoculum Capsules
Study NCT03163784 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antibiotic
Description: Antibiotic pre-treatment
Study NCT03163784 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Antibiotic Placebo
Description: Placebo tablets manufactured to mimic antibiotics
Study NCT03163784 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antibiotic Placebo
Description: Placebo tablets manufactured to mimic antibiotics
Study NCT02730052 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Omron 9200T plus Telemonitoring
Description: Telemonitoring of the self-measured blood pressure at home. After each blood pressure measurement the values are transmitted to and stored into a central station where a condensed weekly report is elaborated and delivered to the doctor (investigator).
Study NCT02730052 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Omron 9200T without Telemonitoring
Description: Self-measured blood pressure at home and register the values in a diary card. Participants will perform 2 consecutive blood pressure measurements twice a day for a 7 day period, previous to the visit to the doctor's (investigator) office.